GLP-1 in Mississippi: coverage & how to get it
What Mississippi Medicaid covers for weight loss (as of April 2026), how the new Medicare bridge fits in, and every legitimate route to the medication: the programs we recommend, buying direct, and the compounded route. We report the policy; we don't give medical advice.
Mississippi Medicaid covers GLP-1s for weight loss
Mississippi is one of just 13 states whose Medicaid program covers GLP-1 medications for the obesity indication. Coverage is typically behind prior authorization, so your prescriber will need to document that you meet the state's criteria. You may pay little or nothing for the drug if you qualify. Confirm the specifics with your plan.
Source: Kaiser Family Foundation, cross-checked against a 50-state Medicaid tracker · as of April 2026. Coverage rules change often, so confirm with your own plan.
Who qualifies for Medicaid in Mississippi
Mississippi has not expanded Medicaid, so many low-income adults do not qualify for the program at all. If you are not Medicaid-eligible, the realistic routes are a commercial or employer plan, the Medicare Bridge if you are 65 or older, or paying cash.
The diabetes route in Mississippi
The coverage above is the weight-loss (obesity) indication. Like nearly every state, Mississippi Medicaid also covers GLP-1s for type-2 diabetes, a separate and broader pathway if you have that diagnosis. This is policy reporting, not medical advice.
What Mississippi's Medicaid drug list says
Mississippi Medicaid covers select anti-obesity agents subject to PA criteria. Preferred agents: Contrave (age 18+), Saxenda (age 12+), and Wegovy (age 12+); Xenical (age 12+) is non-preferred. Qsymia, phentermine, and Evekeo/amphetamine are NOT covered. Coverage is limited to only one obesity product at a time (no concurrent use of two or more anti-obesity agents). Saxenda and Wegovy are GLP-1 agonists and are contraindicated for concomitant use with other GLP-1 agonists (e.g., Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Bydureon, Byetta) or DPP-4 inhibitors; they should be avoided in patients with a history of medullary thyroid carcinoma or MEN type 2. Obesity medications are not covered during pregnancy or breastfeeding. Non-preferred drugs require PA review.
Source: Mississippi Medicaid official criteria, also see the full preferred drug list. Coverage changes often, so confirm the current rules with your plan.
On Medicare in Mississippi?
Traditional Medicare has generally not covered GLP-1s for weight loss alone. But a federal Medicare GLP-1 "Bridge" demonstration starts July 1, 2026, roughly $50/month for Wegovy or Zepbound for obesity, in participating plans. Coverage can also apply when the drug is prescribed for a covered condition such as heart disease. This is national, so it applies to Mississippi residents on Medicare the same as anywhere else.
How to get GLP-1 in Mississippi
If you qualify for Mississippi Medicaid coverage, ask your prescriber to bill it first. If you pay out of pocket or are not eligible, the telehealth programs we recommend operate in most states. Each is scored against our 31-point methodology, and no provider pays us anything.
Other above-board routes: buy the brand drug direct from the manufacturer (NovoCare / LillyDirect, roughly $199–$499/mo), or weigh the cheaper but not-FDA-approved compounded route. Compare the real all-in monthly cost of every option on our comparison page and price index.
How we stay independent
State coverage changes fast, and several states added or dropped GLP-1 coverage across 2025–2026. We date every figure and link the primary source; if something here is out of date, we log the fix publicly. Tell us. Provider rankings are locked against our methodology, and we take no money from any provider we cover (what our independence costs us). This is policy reporting, not medical, legal, or eligibility advice. Confirm coverage with your own plan and clinician.
← See GLP-1 coverage for every state · Find your best-fit provider →
Get the monthly research digest
One plain-English email a month: new study findings, price changes, and safety updates. No spam, ever.